Wednesday, Nov 04, 2020 8:30a -
Friday, Nov 06, 2020 5:30p
United States, United States 00000
Lectures & Conferences
Built with Inflammasome Therapeutics, GSK, and Novartis, the 2nd Inflammasome Therapeutics Summit is the only industry focused meeting dedicated to solving the challenges of targeting the inflammasome to develop clinically effective therapeutics.
This year's summit will once again unite thought leaders in inflammasome drug development to discuss the latest clinical developments, share novel inflammatory pathways outside of NLRP3, the development of the NLRP3 pathway and translate these into clinically effective therapeutics.
Dedicated to overcoming challenges in developing clinically effective inflammasome therapeutics, this comprehensive discussion and networking forum will enable you to:
- Optimize your clinical trial design and hear the latest readouts from the clinic
- Deepen your biological understanding of how the inflammasome is activated and regulated at a cellular level
- Identify novel inflammasome pathways focussing not only on NLRP-3 but looking beyond and outside of this exciting pathway
- Determine which diseases the inflammasome is driving and therefore which have the most therapeutic potential commercially and clinically
New for this year, you'll have two parallel tracks of learning and 31 speakers, sharing highly anticipated case studies and lessons learned, exclusively focused on discovery and translational challenges. Don't miss the opportunity to be part of the force accelerating the development of inflammasome therapeutics.
Digital Conference Only - Industry Pricing: USD 1749.0,
Digital Conference Only - Academic Pricing: USD 1196.0
Speakers: Colin Green, Co-founder and Chief Scientific Officer, OcuNexus Therapeutics, Giulio Maria Pasinetti, The Saunders Family Chair and Professor of Neurology Professor Department of Neurology, Icahn school of Medicine at Mount Sinai, Daniel Bachovchin, Assistant Professor, Memorial Sloan Kettering Cancer Center, Juan Pablo De Rivero Vaccari, Research Assistant Professor, University of Miami Miller School of Medicine, Kate Fitzgerald, Principal Investigator, Umass Medical School, Marcelo Hill, Chief Scientific Officer and Founder, ARDAN ImmunoPharma, Rebecca Coll, Principal Investigator, Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Hal Hoffman, Professor of Pediatrics and Medicine, Rady Children's Hospital of San Diego, Matt Devalaraja, Chief Scientific Officer, Corvidia Therapeutics, Robert Keane, Professor, Physiology, Biophysics and Neurological Surgery, University of Miami, Karen Cashmere, Chief Commercial Officer, Zyversa, Paul Ashton, Chief Executive Officer, Inflammasome Therapeutics, Lee Simon, Consultant, SDG LLC, Johannes Grosse, Senior Director, Vir Biotechnology, Jenny Ting, Distinguished Professor, Genetics, UNC School of Medicine, Vishal Singh, Assistant Professor, Nutritional Sciences and Microbiome, Penn State University, Manon Jansen, Senior Clinical Scientist, Centre for Human Drug Research, Yiumo Chan, Chief Scientific Officer, Twi Biotechnology, Mike Crackower, Head, Research and Development, Ventus Therapeutics, Joanne Lim, Senior Scientist, Cellular Immunology, Codiak Biosciences, Pablo Pelegrin, Scientific Deputy Director and Principal Investigator, Biomedical Research Institute of Murcia, Anil Goyal, Chief Scientific Officer, Immvention Therapeutics, William T. Stewart, Chief Executive Officer, TherimuneX, Meredith Gregory-Ksander, Associate Scientist Schepens Eye Research Institute, Massachusetts Eye and Ear Hospital, SY Seong Chief, Executive Officer, Shaperon, Denisa D. Wagner, Professor, Paediatrics, Boston Children's Hospital, Kate Schroder, Director IMB Centre for Inflammation and Disease Research, The University of Queensland, Iain Kilty, Chief Scientific Officer, Quench Bio, Vincent Gruber, Director of New Technology, JEEN International Corporation, Scott Bowers, Associate Director, Preclinical Pharmacology, Horizon Therapeutics, Hao Wu, Senior Investigator, Harvard Medical School